AIM ImmunoTech Inc. (AIM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AIM ImmunoTech Inc. (AIM) Healthcare & Pipeline Overview

AIM ImmunoTech Inc. is a biotechnology company specializing in the research and development of immunomodulatory therapies, including Ampligen and Alferon N Injection, targeting cancers, viral diseases, and immune disorders. The company operates within the competitive biotechnology sector, focusing on novel treatments.

What Is the Investment Thesis for AIM?

AIM ImmunoTech operates in the high-risk, high-reward biotechnology sector. A key value driver is the potential approval and commercialization of Ampligen for multiple indications, particularly for chronic fatigue syndrome and various cancers. Successful clinical trial outcomes and regulatory approvals could significantly boost the company's valuation. The company's high negative profit margin of -14123.4% and gross margin of -133.0% highlight the financial risks. Upcoming clinical trial results for Ampligen in cancer and viral disease indications represent potential catalysts. Investors should closely monitor these developments and the company's ability to secure additional funding to sustain operations.

Based on FMP financials and quantitative analysis

AIM Key Highlights

Market capitalization of $0.00B indicates a micro-cap company with substantial growth potential but also higher risk.

• Profit margin of -14123.4% reflects significant ongoing research and development expenses and a lack of current product revenue.
• Gross margin of -133.0% suggests that the cost of producing existing products exceeds revenue generated from sales.
• Beta of 1.25 indicates that the stock is more volatile than the market, reflecting the speculative nature of biotechnology investments.
• The company has 21 employees, indicating a small, focused team primarily engaged in research and development activities.

Who Are AIM's Competitors?

AIM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AIM's Key Strengths?

Proprietary drug formulations (Ampligen and Alferon N Injection).

• Focus on niche markets with unmet medical needs.
• Experienced management team.
• Established research and development capabilities.

What Are AIM's Weaknesses?

Limited financial resources.

• High dependence on clinical trial outcomes.
• Negative profit and gross margins.
• Small number of employees.

What Could Drive AIM Stock Higher?

Clinical trial results for Ampligen in pancreatic cancer.

• Clinical trial results for Ampligen in non-small cell lung cancer.
• Regulatory decisions regarding Ampligen's approval for chronic fatigue syndrome.
• Expansion of clinical trials to include additional cancer and viral disease indications.
• Pursuit of strategic partnerships with pharmaceutical companies.

What Are the Key Risks for AIM?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for Ampligen.
• Unfavorable clinical trial results.
• Limited financial resources to support research and development.
• Competition from larger pharmaceutical companies with greater resources.
• Patent expirations and generic competition.

What Are the Growth Opportunities for AIM?

• Expansion of Ampligen's Indications: AIM ImmunoTech has the opportunity to expand the use of Ampligen to treat a wider range of cancers and viral diseases. The market for cancer therapeutics is projected to reach $286 billion by 2026. Positive clinical trial results in indications like pancreatic cancer or non-small cell lung cancer could significantly increase Ampligen's market potential and drive revenue growth. The timeline for this growth depends on successful trial outcomes and regulatory approvals.
• Commercialization of Alferon N Injection: Alferon N Injection, used for the treatment of genital warts, presents a steady revenue stream for AIM ImmunoTech. The global genital warts treatment market is expected to grow, driven by increasing awareness and diagnosis rates. AIM ImmunoTech can capitalize on this growth by expanding its marketing and distribution efforts. This represents a near-term growth opportunity with potential for incremental revenue gains.
• Partnerships and Collaborations: AIM ImmunoTech can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. Collaborations can provide access to additional funding, expertise, and distribution networks. The timeline for securing partnerships is uncertain but could significantly enhance the company's growth prospects.
• Advancements in Myalgic Encephalomyelitis (ME/CFS) Treatment: Ampligen's potential in treating ME/CFS represents a significant growth opportunity. The market for ME/CFS treatments is underserved, and effective therapies could generate substantial revenue. Positive clinical trial results and regulatory approval for this indication would be a major catalyst for AIM ImmunoTech. This represents a medium-term growth opportunity with high potential impact.
• Development of Therapies for Post-COVID Conditions: AIM ImmunoTech is exploring the use of Ampligen for treating post-COVID conditions. The prevalence of long COVID is creating a growing market for effective treatments. Success in this area could lead to significant revenue opportunities. The timeline for this growth depends on clinical trial outcomes and regulatory approvals, representing a medium-term opportunity.

What Are AIM's Competitive Advantages?

• Proprietary drug formulations (Ampligen and Alferon N Injection).
• Patent protection for its key products and technologies.
• Specialized expertise in immunomodulatory therapies.
• Established relationships with researchers and clinicians.

What Does AIM Do?

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., was founded in 1966 and rebranded in August 2019. Headquartered in Ocala, Florida, the company is dedicated to the research and development of therapeutics designed to combat a range of cancers, viral diseases, and immune-deficiency disorders. AIM ImmunoTech's flagship products include Ampligen (rintatolimod), a double-stranded ribonucleic acid molecule intended for the treatment of chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a natural-source alpha interferon product used in the treatment of genital warts. The company's development pipeline also explores the potential of Ampligen in treating various cancers, including pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers. Furthermore, AIM ImmunoTech is investigating Ampligen's efficacy against myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. AIM ImmunoTech operates primarily in the United States, focusing on bringing innovative immunomodulatory therapies to market.

What Products and Services Does AIM Offer?

• Researches and develops therapeutics for cancers.
• Develops treatments for viral diseases.
• Creates therapies for immune-deficiency disorders.
• Focuses on immunomodulatory drugs.
• Manufactures and markets Ampligen (rintatolimod) for chronic fatigue syndrome.
• Produces and sells Alferon N Injection (Interferon alfa) for genital warts.

How Does AIM Make Money?

• Develops and patents novel immunomodulatory therapies.
• Conducts clinical trials to demonstrate safety and efficacy of its drugs.
• Seeks regulatory approvals from the FDA for commercialization.
• Manufactures and markets approved drugs directly or through partnerships.

What Industry Does AIM Operate In?

AIM ImmunoTech operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant competition. The market for immunomodulatory therapies is expanding, driven by increasing prevalence of cancers, viral diseases, and immune disorders. Companies like AIM ImmunoTech are striving to develop innovative treatments to address unmet medical needs. The industry is subject to stringent regulatory oversight by bodies such as the FDA, requiring extensive clinical trials and approvals before commercialization. Success in this sector depends on scientific innovation, clinical trial outcomes, and effective commercialization strategies.

Who Are AIM's Key Customers?

• Patients suffering from chronic fatigue syndrome.
• Patients with genital warts.
• Patients with various types of cancers.
• Healthcare providers prescribing AIM ImmunoTech's products.

The most recent 11 insider filings for AIM ImmunoTech Inc. break down as 2 sales and 9 purchases. On net that is roughly 153K shares acquired (about $155K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: AIM ImmunoTech Inc.

Revenue for AIM ImmunoTech Inc. came in at $26K during Q2 FY2026, a 18.2% improvement versus the preceding quarter. The company recorded a net loss of $3.8M, with diluted EPS of $-0.22. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this unknown Healthcare company. Across the four most recent quarters, AIM averaged $-0.96 in diluted EPS.

AIM Valuation & Market Position

Relative to its peer group, AIM's quantitative score of 18/100 is below the peer average of 88/100.

Return on equity for AIM ImmunoTech Inc. stands at 261.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 1.01 indicates the company holds enough short-term assets to cover its near-term obligations.

AIM ImmunoTech Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

AIM ImmunoTech Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 755.3% below estimates on average.

Company Profile

AIM ImmunoTech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ocala, US. The company is led by CEO Thomas K. Equels. AIM has traded publicly since 1995.

AIM Financials

AIM Latest News

AIM Analyst Consensus

AIM MoonshotScore

Latest AIM ImmunoTech Inc. Analysis

What Investors Ask About AIM ImmunoTech Inc. (AIM) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources